Characterization of IIPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class Ill phosphoinositide 3-kinase

被引:210
作者
Bago, Ruzica [1 ]
Malik, Nazma [1 ]
Munson, Michael J. [1 ]
Prescott, Alan R. [2 ]
Davies, Paul [1 ]
Sommer, Eeva [1 ]
Shpiro, Natalia [1 ]
Ward, Richard [3 ]
Cross, Darren [3 ]
Ganley, Ian G. [1 ]
Alessi, Dario R. [1 ]
机构
[1] Univ Dundee, Coll Life Sci, MRC, Prot Phosphorylat & Ubiquitylat Unit, Dundee DD1 5EH, Scotland
[2] Univ Dundee, Coll Life Sci, Div Cell Signalling & Immunol, Dundee DD1 5EH, Scotland
[3] AstraZeneca, Oncol iMED, Alderley Pk SK10 4TG, Cheshire, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
mammalian target of rapamycin (mTOR); N-Myc downstream-regulated gene-1 (NDRG1); phosphoinositide 3-kinase (PI3K); protein lcinase inhibitor; signal transduction inhibitor; CLASS-II PI3K; IN-VIVO; BREAST-CANCER; MTOR COMPLEX; ACTIVATION; AKT; IDENTIFICATION; DOMAINS; CELLS; PDK1;
D O I
10.1042/BJ20140889
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Vps34 (vacuolar protein sorting 34) class III PI3K (phosphoinositide 3-Idnase) phosphorylates PtdIns (phosphatidylinositol) at endosomal membranes to generate PtdIns(3)P that regulates membrane trafficking processes via its ability to recruit a subset of proteins possessing PtdIns(3)P-binding PX (phox homology) and FYVE domains. In the present study, we describe a highly selective and potent inhibitor of Vps34, termed VPS34-IN1, that inhibits Vps34 with 25 nM IC50 in vitro, but does not significantly inhibit the activity of 340 protein kinases or 25 lipid ldnases tested that include all isoforms of class I as well as class II PI3Ks Administration of VPS34-IN1 to cells induces a rapid dose-dependent dispersal of a specific PtdIns(3)Pbinding probe from endosome membranes, within 1 mm, without affecting the ability of class I PI3K to regulate Akt. Moreover, we explored whether SGK3 (serum- and glucocorticoid-regulated kinase-3), the only protein kinase known to interact specifically with PtdIns(3)P via its N-terminal PX domain, might be controlled by Vps34. Mutations disrupting PtdIns(3)P binding ablated SGK3 kinase activity by suppressing phosphorylation of the T-loop [PDK1 (phosphoinositide-dependent kinase 1) site] and hydrophobic motif (mammalian target of rapamycin site) residues. VPS34-IN1 induced a rapid '--'50-60% loss of SGK3 phosphorylation within 1 mffi VPS34-IN1 did not inhibit activity of the SGK2 isoform that does not possess a PtdIns(3)P-binding PX domain. Furthermore, class I PI3K inhibitors (GDC-0941 and BKM120) that do not inhibit Vps34 suppressed SGK3 activity by '-'40%. Combining VPS34-IN1 and GDC-0941 reduced SGK3 activity similar to 80-90%. These data suggest SGK3 phosphorylation and hence activity is controlled by two pools of PtdIns(3)P. The first is produced through phosphorylation of PtdIns by Vps34 at the endosome. The second is due to the conversion of class I PI3K product, PtdIns(3,4,5)P3 into PtdIns(3)P, via the sequential actions of the PtdIns 5-phosphatases [SHIP1/2 (Src homology 2-domain-containing inositol phosphatase 1/2)] and PtdIns 4-phosphatase [INPP4B (inositol polyphosphate 4phosphatase type II)]. VPS34-IN1 will be a useful probe to delineate physiological roles of the Vps34. Monitoring SGK3 phosphorylation and activity could be employed as a biomarker of Vps34 activity, in an analogous manner by which Akt is used to probe cellular class I PI3K activity. Combining class I (GDC0941) and class III (VPS34-IN1) PI3K inhibitors could be used as a strategy to better analyse the roles and regulation of the elusive class II PI3K.
引用
收藏
页码:413 / 427
页数:15
相关论文
共 67 条
  • [1] Agoulnik IU, 2011, ONCOTARGET, V2, P321
  • [2] Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha
    Alessi, DR
    James, SR
    Downes, CP
    Holmes, AB
    Gaffney, PRJ
    Reese, CB
    Cohen, P
    [J]. CURRENT BIOLOGY, 1997, 7 (04) : 261 - 269
  • [3] 3-phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase
    Alessi, DR
    Deak, M
    Casamayor, A
    Caudwell, FB
    Morrice, N
    Norman, DG
    Gaffney, P
    Reese, CB
    MacDougall, CN
    Harbison, D
    Ashworth, A
    Bownes, M
    [J]. CURRENT BIOLOGY, 1997, 7 (10) : 776 - 789
  • [4] Myotubularin Phosphoinositide Phosphatases in Human Diseases
    Amoasii, Leonela
    Hnia, Karim
    Laporte, Jocelyn
    [J]. PHOSPHOINOSITIDES AND DISEASE, 2012, 362 : 209 - 233
  • [5] The regulation and function of Class III PI3Ks: novel roles for Vps34
    Backer, Jonathan M.
    [J]. BIOCHEMICAL JOURNAL, 2008, 410 (01) : 1 - 17
  • [6] Targeting the PI3K signaling pathway in cancer therapy
    Bartholomeusz, Chandra
    Gonzalez-Angulo, Ana Maria
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (01) : 121 - 130
  • [7] Cell-cycle-dependent binding kinetics for the early endosomal tethering factor EEA1
    Bergeland, Trygve
    Haugen, Linda
    Landsverk, Ole J. B.
    Stenmark, Harald
    Bakke, Oddmund
    [J]. EMBO REPORTS, 2008, 9 (02) : 171 - 178
  • [8] The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB
    Biondi, RM
    Kieloch, A
    Currie, RA
    Deak, M
    Alessi, DR
    [J]. EMBO JOURNAL, 2001, 20 (16) : 4380 - 4390
  • [9] Bruhn Maressa A, 2013, Cancer Manag Res, V5, P281, DOI 10.2147/CMAR.S35178
  • [10] Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo
    Calleja, Veronique
    Alcor, Damien
    Laguerre, Michel
    Park, Jongsun
    Vojnovic, Borivoj
    Hemmings, Brian A.
    Downward, Julian
    Parker, Peter J.
    Larijani, Banafshe
    [J]. PLOS BIOLOGY, 2007, 5 (04) : 780 - 791